Publications by authors named "E De Prez"
Pulmonary congestion (PC) is common in hemodialysis (HD) patients. We explored the association of anemia and pulmonary congestion in HD patients. A prospective pilot observational study included 18 patients on maintenance HD.
View Article and Find Full Text PDFArticle Synopsis
- * Biomarkers like urinary leucine aminopeptidase (LAP) showed significant increases in AKI patients, indicating acute tubular injury, while other biomarkers like NGAL and CCL-14 showed no significant differences between AKI and non-AKI groups.
- * Elevated blood levels of suPAR and cystatin C at hospitalization linked to worse outcomes, such as longer ICU stays and higher mortality, highlighting their role as important prognostic indicators regardless of whether AKI develops.
Article Synopsis
- - Aristolochic acid nephropathy (AAN) is a serious kidney condition caused by consuming substances with aristolochic acids, often found in certain Chinese herbal remedies and contaminated food, leading to kidney damage and chronic conditions.
- - Research used rodent models to study how AAN progresses from acute kidney injury (AKI) to chronic kidney disease (CKD), revealing that initial injury leads to inflammation and eventual severe kidney deterioration.
- - Four key players in this transition were identified: tubular epithelial cells, endothelial cells, inflammatory cells, and myofibroblasts, highlighting their roles in kidney damage and potential future research directions.
Despite the advances in targeted therapies and immunotherapy for non-small cell lung cancer (NSCLC) patients, the intravenous administration of carboplatin (CARB) and paclitaxel (PTX) in well-spaced cycles is widely indicated for the treatment of NSCLC from stage II to stage IV. Our strategy was to add a controlled-release cisplatin-based dry-powder for inhalation (CIS-DPI-ET) to the conventional CARB-PTX-IV doublet, administered during the treatment off-cycles to intensify the therapeutic response while avoiding the impairment of pulmonary, renal and haematological tolerance of these combinations. The co-administration of CIS-DPI-ET (0.
View Article and Find Full Text PDFDespite recent advances, platinum-based chemotherapy (partially composed of cisplatin, CIS) remains the backbone of non-small-cell lung cancer treatment. As CIS presents a cumulative and dose-limiting nephrotoxicity, it is currently administered with an interruption phase of 3-4 weeks between treatment cycles. During these periods, the patient recovers from the treatment side effects but so does the tumour.
View Article and Find Full Text PDF